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Background: Sterile Alpha Motif and HD domain-containing protein 1 (SAMHD1) is a recently identified host factor
that restricts HIV-1 replication in dendritic and myeloid cells. SAMHD1 is a dNTPase that presumably reduces the
cellular dNTP levels to levels too low for retroviral reverse transcription to occur. However, HIV-2 and SIV encoded
Vpx counteracts the antiviral effects of SAMHD1 by targeting the protein for proteasomal degradation. SAMHD1 is
encoded by a multiply spliced mRNA and consists of 16 coding exons.
Results: Here, we identified two naturally occurring splice variants lacking exons 8–9 and 14, respectively. Like
wildtype SAMHD1, both splice variants localize primarily to the nucleus, interact with Vpx, and retain some
sensitivity to Vpx-dependent degradation. However, the splice variants differ from full-length SAMHD1 in their
metabolic stability and catalytic activity. While full-length SAMHD1 is metabolically stable in uninfected cells, both
splice variants were inherently metabolically unstable and were rapidly degraded even in the absence of Vpx. Vpx
strongly increased the rate of degradation of full-length SAMHD1 and further accelerated the degradation of the
splice variants. However, the effect of Vpx on the splice variants was more modest due to the inherent instability of
these proteins. Analysis of dNTPase activity indicates that neither splice variant is catalytically active.
Conclusions: The identification of SAMHD1 splice variants exposes a potential regulatory mechanism that could
enable the cell to control its dNTPase activity on a post-transcriptional level.
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HIV-2 and many SIV isolates encode an accessory pro-
tein, Vpx, that is required for replication in myeloid cells
[1-4]. HIV-1 does not encode a vpx gene; interestingly,
however, the presence of Vpx enhances replication of
HIV-1 in monocyte-derived macrophages, dendritic
cells, and the differentiated THP-1 cell line [1,5-8] sug-
gesting the presence of a Vpx-sensitive host restriction
factor. Also, Vpx was shown to rescue HIV-1 but not
HIV-2 or SIV from an interferon-induced antiviral state
[9]. A Vpx-sensitive restriction factor was recently iden-
tified as Sterile Alpha Motif and HD domain-containing
protein 1 (SAMHD1), which was found to be targeted
for proteasomal degradation by Vpx [10-13]. Mutations
in the SAMHD1 gene have been implicated with* Correspondence: kstrebel@nih.gov
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reproduction in any medium, provided the orAicardi-Goutieres Syndrome (AGS), a disease that is
associated with increased production of interferon-alpha
and thus mimics congenital virus infections [14,15]. This
suggests SAMHD1, along with other AGS-associated
proteins (e.g. TREX1 and RNASEH2), may be involved
in the regulation of the innate immune response [16].
Moreover, SAMHD1 was shown to contribute to the re-
striction of HIV-1 in resting CD4+ T cells [17,18].
SAMHD1 has recently been shown to possess dGTP-
dependent dNTPase activity [19,20], and the current
hypothesis is that SAMHD1 is able to deplete the intracel-
lular pool of dNTPs in susceptible cell types to levels
below that required for reverse transcription, thus result-
ing in restriction of HIV-1 replication [19-22].
Here, we describe the identification and characteriza-
tion of two SAMHD1 splice variants that are expressed
naturally together with full-length SAMHD1 in a variety
of cell types. The splice variants identified either lack
exons 8–9 (Δ8-9), eliminating a C-terminal portion of the
HD domain, or exon 14 (Δ14). Like wildtype SAMHD1,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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localization, and they interact with Vpx. However, unlike
wildtype SAMHD1, which is stable in the absence of Vpx,
both splice variants are inherently unstable and are rapidly
degraded even in the absence of Vpx. Pulse/chase analyses
confirmed that Vpx had a strong impact on the degrad-
ation of full-length SAMHD1. Addition of Vpx also
increased the turnover of the splice variants. However, this
effect was more modest because of the inherent instability
of these proteins in the absence of Vpx. Neither splice
variant exhibited dNTPase activity in an in vitro assay,
suggesting they also lack antiviral activity. The identifica-
tion of SAMHD1 splice variants exposes a potential regu-
latory mechanism that could enable a cell to control its
dNTPase activity at a post-transcriptional level.
Results
Cloning and expression of SAMHD1 splice variants
To characterize SAMHD1 and its role in restricting lenti-
viral replication, we cloned SAMHD1 from the mRNA
pool of PMA-differentiated THP-1 cells. SAMHD1Figure 1 Identification and characterization of SAMHD1 splice variant
SAMHD1 splice variants cloned from PMA-treated THP-1 cells. (B) Location
variants. Δ14 primers consist of a forward primer (F14) located in exon 10 a
The resulting PCR product is predicted to be 462 bp long. Δ8-9 primers co
10 and a reverse primer R8/9 in exon 15, resulting in a predicted PCR prod
treated with 100 nM PMA for 24 h and used as template for a PCR reaction
Plasmid controls consisted of 1 ng of pcDNA-SAMHD1 WT, Δ14, or Δ8-9 us
transfected with 5 μg each of pcDNA-SAMHD1 WT, Δ14, or Δ8-9 as indicat
SDS-PAGE. Immunoblot analysis was performed with rabbit polyclonal antispecific cDNA was cloned into pcDNA3.1 either in
untagged form or with an N-terminal HA tag. Interest-
ingly, in addition to the complete 16-exon gene encoding
the 626 residue full-length SAMHD1 protein, we identi-
fied two splice variants lacking exons 8 plus 9 (corre-
sponding to residues 285–354) or exon 14 (residues
502–536), respectively (Figure 1A). To confirm the pres-
ence of these splice variants in differentiated THP-1 cells,
splice-junction specific primers were designed for the se-
lective amplification of alternatively spliced mRNA
(Figure 1B). SAMHD1 WT, Δ14, and Δ8-9 plasmid
DNAs were used as specificity controls. As expected, the
primer set F14/R14 specific for SAMHD1Δ14 showed a
PCR product with SAMHD1Δ14 DNA as template but
not when the wildtype plasmid was used (Figure 1C,
lanes 2 and 3). The Δ8-9 primer set F8/9/R8/9 showed
similar specificity for the Δ8-9 construct (Figure 1C,
lanes 5 and 6). Importantly, when cDNA from PMA-
differentiated THP-1 cells was used as a template, both
primer sets amplified a band of appropriate size indicat-
ing the splice variants are genuinely present in thes. (A) Schematic representation of the SAMHD1 protein and the
of the primers used for the specific amplification of SAMHD1 splice
nd a reverse primer (R14) spanning the junction of exons 13 and 15.
nsist of a forward primer (F8/9) spanning the junction of exons 7 and
uct of 711 bp. (C) cDNA pools were generated from THP-1 cells
using Taq polymerase and the primer sets described in panel B.
ed as template in the PCR reaction, as indicated. (D) HeLa cells were
ed. Total cell extracts were prepared 24 h later and separated on 10%
bodies specific to SAMHD1 (SAM416) and actin, as indicated.
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Similar results were observed for SAMHD1 mRNA from
293 T cells and primary CD4+ T lymphocytes (data not
shown). Notably, HeLa cells express very low amounts of
SAMHD1; and, consistent with this, splice variants were
not identified in these cells (data not shown). Thus, ex-
pression of SAMHD1 splice variants is not a unique
property of THP-1 cells but was found in other
SAMHD1-positive cell lines and primary human T cells
tested.
Differential splicing might be an important mechanism
for the cell to regulate SAMHD1 and its functions.
Therefore, we set out to study the functional properties
of the splice variants as compared to the wildtype pro-
tein. For this purpose, we generated a polyclonal anti-
body to SAMHD1 (SAM416) using recombinant protein
purified from E. coli as previously described [23]. The
antibody readily identified wildtype SAMHD1 and its
splice variants by immunoblotting (Figure 1D) and im-
munocytochemistry (see Figure 2). Interestingly, trans-
fection of constant levels of plasmid DNAs yielded
significant differences in the expression level of the
splice variants relative to the full-length protein. InFigure 2 Immunofluorescence analysis of SAMHD1 WT and
splice variants. HeLa cells were either mock transfected (panel A)
or transfected with 1 μg of pcDNA-SAMHD1 WT (panel B), 5 μg of
Δ14 (panel C), or 4 μg of Δ8-9 (panel D). Total amounts of
transfected DNA were adjusted to 5 μg with empty vector DNA as
necessary. After the transfection, cells were replated onto cover slips,
grown for 24 h, and then fixed with methanol (10 min, -20°C). Cells
were dually stained with rabbit polyclonal antibody to SAMHD1
(SAM416; red) and a mouse monoclonal antibody to lamin-B (green).
Samples were analyzed on a confocal microscope as detailed in
Methods.particular, SAMHD1Δ14 consistently yielded a lower sig-
nal than the wildtype protein in immunoblot analyses
(Figure 1D, lane 2). This was unlikely due to differential
recognition by SAM416 since N-terminally HA-tagged
constructs detected with an anti-HA antibody showed
similar differences in signal intensities (data not shown).
SAMHD1 splice variants exhibit the same nuclear
localization as the wildtype protein
While wildtype SAMHD1 localizes almost exclusively to
the nucleus [14], mutants associated with AGS cause the
protein to be at least partially localized to the cytoplasm
[24], suggesting a possible correlation between SAMHD1
nuclear localization and function. However, recent
evidence has suggested that while SAMHD1 nuclear
localization may not be strictly required for HIV-1
restriction, it may be important for the initiation of Vpx-
dependent degradation of SAMHD1 [25]. Immunocyto-
chemistry of untagged wildtype SAMHD1 transfected
into HeLa cells confirmed the nuclear localization of
SAMHD1 (Figure 2, panel B). Similarly, SAMHD1Δ14
and Δ8-9 revealed exclusively nuclear localization in the
vast majority of transfected cells (Figure 2, panels C and
D). This indicates that sequences encoded by exons 8–9
and 14 are not critical for determining the subcellular
distribution of SAMHD1. Indeed, a KRPR nuclear
localization sequence has recently been mapped to the
N-terminus of SAMHD1 [25].
SAMHD1 splice variants interact with Vpx
Vpx has been shown to render monocytic cells permis-
sive to HIV-1 infection by binding to and causing the
proteosomal degradation of SAMHD1 [10,11]. In order
to determine whether SAMHD1Δ14 and Δ8-9 are sub-
ject to Vpx-dependent degradation, SAMHD1 WT, Δ14,
and Δ8-9 were transfected into HeLa cells together with
increasing amounts of Vpx from SIVmac239. To adjust for
the lower expression of the splice variants, amounts of
transfected DNA were modified to achieve comparable
expression of wildtype SAMHD1 and the splice variants
in the absence of Vpx (Figure 3A, lanes 1, 4, and 7).
Immunoblot analysis showed that levels of wildtype
SAMHD1 were effectively reduced in Vpx expressing
cells (Figure 3A, compare lanes 1 & 2). In contrast, Vpx
had a more subtle effect on the steady-state expression
of SAMHD1 splice variants (Figure 3A, compare lanes 4
and 5, and 7 and 8). In particular, SAMHD1Δ8-9 steady-
state expression appeared to be much less affected by
Vpx than the wildtype protein (Figure 3A, compare lanes
1 and 2 with lanes 7 and 8). Interestingly, the effects of
Vpx on SAMHD1 levels did not increase at higher levels
of Vpx (Figure 3A, compare lanes 2 and 3, 5 and 6, 8
and 9) suggesting that Vpx is saturating in our system
even at the lowest level tested.
Figure 3 Interaction of Vpx and SAMHD1 splice variants. (A) HeLa
cells were transfected with pcDNA-SAMHD1 WT (1 μg), Δ14 (5 μg), or
Δ8-9 (4 μg) as indicated, either without Vpx (lanes 1, 4, 7) or with
increasing amounts (0, 0.25, 0.5 μg) of pCMV-Vpxmac239. Whole cell
extracts were prepared 24 h after transfection and separated on 10%
(SAMHD1, actin) or 15% (Vpx) SDS-PAGE. Immunoblot analysis was
performed with rabbit polyclonal antibodies specific to SAMHD1 and
SIVmac239 Vpx. The SAMHD1 blot was subsequently reprobed with a
rabbit polyclonal antibody to actin. (B) Vpx interacts with SAMHD1
splice variants. HeLa cells were transfected with pcDNA-HA-SAMHD1
WT (2 μg), Δ14 (5 μg), or Δ8-9 (3 μg) together with 0.5 μg of
pCMV-Vpxmac239. Total amounts of transfected DNA were adjusted to
5.5 μg with empty vector DNA as appropriate. MG132 (10 μM final
concentration) was added to the samples 20 h post-transfection and
cells were lysed 4 h later and processed for immunoprecipitation
with HA-beads as described in Methods. Immunoprecipitated proteins
(IP: α-HA) together with input lysate (input) were separated by
SDS-PAGE and immunoblot analysis was performed with antibodies
to SAMHD1 or Vpx as indicated.
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Vpx on the expression of SAMHD1 splice variants
was due to a lack of protein-protein interaction, co-
immunoprecipitation studies were performed employing
N-terminally HA-tagged SAMHD1 variants, which were
cotransfected into HeLa cells together with Vpx
(Figure 3B). To minimize effects due to SAMHD1 deg-
radation, cells were treated with the proteasome inhibi-
tor MG132 for 4 h prior to cell lysis. Consistent withprevious reports [10-12], wildtype SAMHD1 interacted
with Vpx as indicated by the co-immunoprecipitation of
Vpx in the SAMHD1 pulldowns (Figure 3B, bottom
panel, lane 1). Interestingly, both SAMHD1 splice var-
iants also interacted with Vpx as indicated by the effi-
cient co-immunoprecipitation of Vpx (Figure 3B, lanes
2–3). Vpx was not pulled down by HA antibodies in the
absence of SAMHD1 (Figure 3B, lane 4) attesting to the
specificity of the assay. These results indicate that regions
in SAMHD1 missing in the splice variants are not strictly
required for Vpx binding. This is consistent with recent
data suggesting a C-terminal region of SAMHD1 is
involved in the interaction with Vpx [26,27].
SAMHD1 splice variants remain sensitive to Vpx-induced
degradation
To assess whether the differences in SAMHD1 levels
observed for wildtype SAMHD1 and its splice variants
in Figure 3A in the presence of Vpx are due to differ-
ential sensitivity to Vpx-dependent degradation, pulse-
chase analyses were performed and proteins were
immunoprecipitated with SAM416 antibody as detailed
in Methods (Figure 4A). Note that in this experiment
equal amounts of SAMHD1 vectors were transfected.
Protein bands were quantified by PhosphorImage ana-
lysis (Figure 4B). We found that wildtype SAMHD1 was
metabolically stable in the absence of Vpx with no ap-
parent loss of protein during the 2 h observation period
(Figure 4B WT, open circles). However, in the presence
of Vpx, SAMHD1 was rapidly degraded with a half-life
of ~25 minutes (Figure 4B WT, closed circles). Interest-
ingly, at the pulse time point, the signals obtained for
the splice variants were comparable to those of wildtype
SAMHD1 (Figure 4A, lanes “0”). This suggests that dif-
ferences in steady state levels observed in Figure 3A are
not due to differences in mRNA stability or protein ex-
pression. Instead, both the Δ14 and Δ8-9 splice variants
were inherently unstable even in the absence of Vpx
and had half-lives of ~45 and ~35 min, respectively
(Figure 4B Δ8-9 & Δ14, open circles). Co-expression of
Vpx further increased their rate of degradation
(Figure 4B, Δ8-9 & Δ14, closed circles). Because of the
inherent instability of the SAMHD1 splice variants, the
differences in degradation kinetics in the presence or
absence of Vpx were less pronounced than in the wild-
type protein. However, the half-lives of ~20-30 minutes
for the splice variants, which result from the combined
effects of their instability plus the additional impact of
Vpx, are very similar to the 25 minutes half-life
observed for wildtype SAMHD1 in the presence of Vpx.
SAMHD1 splice variants lack dNTPase activity
Several studies have recently proposed that the HIV-1
restrictive activity of SAMHD1 is due to its ability to
Figure 4 Pulse-chase analysis of SAMHD1 in the presence or absence of Vpx. HeLa cells were transfected with 4.5 μg each of
pcDNA-SAMHD1 WT, Δ14, or Δ8-9 either with 0.5 μg of empty vector DNA (no Vpx) or together with 0.5 μg of pCMV-Vpxmac239 (Vpx(+)). Thus,
the SAMHD1:Vpx DNA ratio was 10:1 for all samples. Pulse-chase analysis was performed 24 h later by labeling cells for 15 minutes with
[35S]-methionine/cysteine and chasing for up to 2 h as described in Methods. Labeled SAMHD1 proteins were immunoprecipitated using SAM416
antiserum, separated on SDS-PAGE, and visualized by fluorography. Protein bands were quantified by PhosphorImage analysis and plotted as a
function of time. Signal intensity at the 0 time points was defined as 100%. Error bars reflect the standard error of the mean from two
independent experiments.
Figure 5 Analysis of dNTPase activity in SAMHD1 splice
variants. (A) HeLa cells were transfected with pcDNA-HA-SAMHD1
WT, Δ14, Δ8-9 or a catalytically inactive SAMHD1 mutant, H206A/
D207A (AA). Amounts of transfected DNA were adjusted to
achieve comparable protein levels. Cell extracts were prepared
24 h later and used for immunoprecipitation with HA-beads as
described in Methods. 15% of the total immunoprecipitated
SAMHD1 proteins were separated on SDS-PAGE and detected by
immunoblot using SAMHD1 specific antiserum. (B) The remaining
immunoprecipitated protein was used in a dTTPase assay directly
on the beads using 0.5 μCi α-[32P] dTTP and conditions reported
by Lahouassa et al. [21] and described in Methods. Where
indicated, 200 μM dGTP was added to the reaction buffer.
Released triphosphate (PPP) was separated by polyethyleneimine
(PEI)-cellulose thin layer chromatography using 0.8 M LiCl as the
mobile phase.
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the dNTP pool to a level insufficient to support reverse
transcription of the retroviral genome, as also suggested
by Kim et al. 2012 [22]. Based on these findings, we next
determined the dNTPase activity of our SAMHD1 splice
variants. In order to do so, HA-SAMHD1 proteins were
immunoprecipitated from transfected HeLa cells using
HA beads. As before, experimental parameters were
adjusted to yield comparable levels of protein to use in
the assay (Figure 5A, lanes 1–3). As a control, a catalyt-
ically inactive mutant, SAMHD1 AA [19], was con-
structed as detailed in Methods and included in this
analysis (Figure 5A, lane 4). Immunoprecipitates were
used directly in a dTTPase assay as detailed in Methods
using the conditions described by Lahouassa et al. [21].
In our assay, SAMHD1 dNTPase activity results in the
release of triphosphate (PP32P) from α-[32P]-dTTP,
which was separated from uncleaved dTTP by thin layer
chromatography. As expected, wildtype SAMHD1 exhib-
ited catalytic activity (Figure 5B, lane 1), and this activity
was enhanced in the presence of unlabeled dGTP
(Figure 5B, lane 2). The catalytically inactive SAMHD1
AA variant failed to release more than background levels
of triphosphate from the dTTP substrate even when
dGTP was added (Figure 5B, compare lanes 7–8 and
9–10). Of note, neither SAMHD1 Δ14 (Figure 5B,
lanes 3–4) nor Δ8-9 (lanes 5–6) was able to release
triphosphate in this assay indicating that these splice
variants are catalytically inactive.
To assess the ability of our splice variants to restrict
HIV-1 infection, we stably transduced U937 cells using a
lentiviral vector system containing the indicated splicing
variants (Additional file 1: Figure S1A). Wild type
SAMHD1 clearly restricted HIV-1 infection of U937
Figure 6 Location of SAMHD1 exons 8–9 and exon 14
sequences on SAMHD1 structural model. A representation of the
SAMHD1 crystal structure was generated using Swiss PDB viewer
([32] and http://www.expasy.org/spdbv/) based on published
coordinates from Goldstone et al. (PDB ID: 3U1N [19]). Active site
residues His167, His206, Asp207 and Asp311 are shown in red and are
highlighted by a red circle. The region encoded by exons 8 and 9
(residues 285–354) is shown in green. The region encoded by exon
14 (residues 502–536), for which only partial structural information is
available, is shown in light blue. The dGTP binding region of
SAMHD1 as determined by Goldstone et al. [19] is indicated as well.
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one of the two splice variants inhibited HIV-1 infection
(Additional file 1: Figure S1B). Of note, expression of the
splice variants was poor when compared to the wild type
protein (Additional file 1: Figure S1A). When wildtype
SAMHD1 expression was reduced to levels comparable
to those observed for the splice variants by titrating the
transducing vector, no restriction of HIV-1 was observed
even with wild type SAMHD1 (data not shown). There-
fore, the results from this experiment do not conclu-
sively prove or disprove restriction capacity of the
SAMHD1 splice variants. However, since dNTPase ac-
tivity of SAMHD1 appears to be required for its antiviral
activity [21], our results would suggest that the Δ14 and
Δ8-9 splice variants lack restricting activity.
Discussion
Nearly 90% of human gene sequences consist of introns
that must be removed through splicing (for review see
[28]). Alternative splicing allows the production of dif-
ferent proteins from a single gene. Indeed, about 80% of
genetic variability introduced through alternative spli-
cing falls within open reading frames [29]. Recent
genome-wide analyses of alternative splicing indicate
that up to 70% of human genes may have alternative
splice forms, suggesting that alternative splicing together
with various posttranslational modifications plays a
major role in expanding proteome complexity [30]. Pro-
teins produced by alternative splicing can differ from the
full-length product in their biophysical and biological
properties at the level of protein stability, protein modi-
fication, intracellular localization, or surface expression
[28]. Thus, alternative splicing is a fundamental aspect
of post-transcriptional gene regulation in eukaryotic cells
with significant functional implications.
The 3.2 kb SAMHD1 mRNA (NM_015474) consists of
16 exons that have to be post-transcriptionally spliced
from the 62 kb pre-mRNA. Recently, a G to A mutation
in the SAMHD1 gene was found in patients with cere-
bral vasculopathy [31]. The mutation localized to the
exon 12 splice-acceptor site and resulted in the skipping
of exon 13. Cell lines carrying this defect in SAMHD1
failed to show SAMHD1 expression suggesting that the
exon 13-deficient splice variant was highly unstable [31].
While the splicing defect observed in cerebral vasculopa-
thy patients was not caused by alternative splicing but,
instead, was induced by a genetic mutation, it neverthe-
less exemplifies the dramatic effects variation in splicing
can have on the biophysical and biomedical properties of
the resulting protein.
In contrast to the exon 13 skipping associated with
cerebral vasculopathy, the splice variants identified in
our study are caused by alternative splicing. Conse-
quently, the proteins expressed from the alternativelyspliced mRNAs would be co-expressed together with
full-length SAMHD1 protein. Interestingly, the produc-
tion of these splice variants is not limited to THP-1 cells.
In fact, both the Δ8-9 and Δ14 variants were identified
in other SAMHD1-expressing cells analyzed, including
primary human CD4+ T cells and the 293 T cell line
(data not shown). This suggests that production of
SAMHD1 splice variants is a general property of
SAMHD1 gene expression and thus may have functional
significance. The regions missing in the splice variants
identified in this study are visualized in Figure 6 on a
representation of the published crystal structure of
SAMHD1 [19]. Active site residues are depicted in red.
The region that is encoded by exons 8 and 9 is shown in
green and encompasses alpha helix 11, which contri-
butes Asp311 to the active site. As mutation of this resi-
due to alanine has been shown to render SAMHD1
catalytically inactive [19], it is not surprising that
SAMHD1 Δ8-9, in which this whole region is missing is
inactive. Why the Δ14 splice variant is catalytically in-
active is less obvious. Exon 14 is part of the C-terminal
domain of SAMHD1 [19], distinct from the active site,
and there is only partial structural information available
for this region (Figure 6, light blue). It is possible that
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and may be required for SAMHD1 function. However, it
is also possible that removal of exon 14 sufficiently
changes or destabilizes the structure to impact the active
site and/or the more distal allosteric dGTP binding re-
gion of SAMHD1.
The fact that our SAMHD1 splice variants are catalyt-
ically inactive but retain the ability to bind Vpx, raises
the possibility that these proteins might act as decoys for
full-length SAMHD1 and interfere with the ability of
Vpx to target the functional protein. Interference studies
are currently in progress to experimentally test this pos-
sibility. However, given the inherent instability of the
two splice variants identified in our study, it seems
more plausible to speculate that alternative splicing of
the SAMHD1 pre-mRNA is a regulatory mechanism
employed by the cells to modulate expression and
function of catalytically active SAMHD1 at a post-
transcriptional level. This view is supported by our
finding that both splice variants can be identified in mul-
tiple cell types. Because of its inherent dNTPase activity,
SAMHD1 is likely to be involved in regulating the cellu-
lar dNTP levels. In non-dividing cells, such as terminally
differentiated macrophages or dendritic cells, there is no
active host DNA replication and SAMHD1 activity con-
tributes to keeping the cellular dNTP level low. This
might in fact explain, at least in part, the resistance of
non-dividing cells to infection by HIV-1 [21,22,33]. In
contrast, in actively dividing cells, e.g. immortalized cell
lines such as 293 T or HeLa or in undifferentiated THP-
1 cells, expression of an active dNTPase might be coun-
terproductive. Still, we noted that the levels of SAMHD1
in differentiated (non-dividing) and undifferentiated
(dividing) THP-1 cells are indistinguishable (data not
shown) suggesting that dNTP levels in these cells may
be regulated by other yet to be identified mechanisms.
Conclusions
While the SAMHD1 splice variants identified here are
less stable than the full-length protein, it is possible that
these or other yet to be identified forms of SAMHD1
may have functional roles in specific cell types or under
specific conditions. In any case, characterization of dif-
ferent SAMHD1 splice variants, like those described
here, not only yields important insight into potential
functional differences of these proteins but also helps
characterize the regions in SAMHD1 involved in
dNTPase activity, HIV-1 restriction, and Vpx-dependent
inactivation.
Methods
Cell culture and transfections
THP-1 cells were maintained in RPMI 1640 media
containing 10% fetal bovine serum. For differentiation,5 million cells were treated with 100 nM phorbol
12-myristate 13-acetate (PMA, Sigma-Aldrich, Inc., St.
Louis MO) in a 6-well plate. Cells were washed after 24 h
and left an additional 24 h in culture prior to harvest.
HeLa cells were propagated in Dulbecco’s modified
Eagles medium (DMEM) containing 10% fetal bovine
serum. For transfection, HeLa cells were grown in
25 cm2 flasks to about 80% confluency (~3x 106 cells).
Cells were transfected using LipofectAMINE PLUSTM
(Invitrogen Corp, Carlsbad CA) following the manufac-
turer’s recommendations. A total of 5–6 μg of plasmid
DNA per 25 cm2 flask was used. Where appropriate,
empty vector DNA was used to adjust total DNA
amounts. Samples were harvested 24 h post-transfection.
Antibodies
Polyclonal antibodies to human SAMHD1 and SIVmac239
Vpx were generated in rabbits immunized with purified
recombinant fusion proteins expressed in E. coli. A
MS2-SAMHD1 fusion protein containing amino acids
1–91 of the MS2 replicase followed by approximately
100 amino acids of a SAMHD1 fragment beginning at
amino acid 416 was used to generate the SAMHD1 anti-
serum (SAM416), whereas the MS2 replicase was fused
to the full length Vpx protein for generation of Vpx anti-
serum. A polyclonal antibody to actin (Sigma-Aldrich,
Inc., St. Louis MO; Cat# A-5060) was used as a loading
control. A mouse monoclonal antibody to human lamin
B (Accurate Chemical & Scientific Corp., Westbury NY;
Cat# BMDV3002) was used to stain the nuclear lamina.
Fluorescently conjugated secondary antibodies used for
immunofluorescence were purchased from Jackson
ImmunoResearch Laboratories Inc. (West Grove PA).
Plasmids
cDNA was generated from total RNA from PMA-
differentiated THP-1 cells using a Superscript III kit and
an oligo dT primer (Invitrogen). The SAMHD1 specific
sequence was then isolated by PCR from the cDNA pool
using forward primer 50 AAT AAG CTA GCG AAA
CCA TGC AGC GAG CCG ATT CCG AG 30 and re-
verse primer 50 TGC TCT AGA TTA CAT TGG GTC
ATC TTT AAA AAG CTG GAC 30. The PCR primers
include Bmt1 and XbaI restriction sites for insertion into
the Bmt1/Xba1 site of pcDNA3.1-APOBEC3G-HA [34].
The reverse primer also contained a stop codon to pre-
vent expression of the C-terminal vector HA tag. This
strategy led to the generation of pcDNA-SAMHD1 WT
encoding the full-length protein as well as pcDNA-
SAMHD1Δ14 and pcDNA-SAMHD1Δ8-9, encoding
splice variants lacking exons 14 and 8–9, respectively.
N-terminally HA-tagged SAMHD1 constructs were gen-
erated from the untagged constructs using similar Bmt1/
Xba1 primers with an N-terminal HA tag included in
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ATG TAT CCA TAT GAC GTT CCA GAT TAC GCT
TGT ACA CAG CGA GCC GAT TCC GAG CAG 30).
An active site mutant (SAMHD1 AA) was created by
introducing a H206A/D207A double alanine mutation
into wildtype SAMHD1 using Quikchange mutagenesis
(Stratagene, Agilent Technologies). Plasmid pCMV-
Vpxmac239 was constructed by replacing the SalI/NotI vif
insert in pVif-HA [35] with the vpx gene from SIV-
mac239. For that purpose, vpx from SIVmac239 was PCR
amplified using primers 50 A CGC GTC GAC ACC
ATG TCA GAT CCC AGG GAG AG 30 (forward) and
50 ATA GTT TAG CGG CCG CGG GTT ATG CTA
GTC CTG GAG G 30 (reverse). These primers include
the Vpx start and stop codons and create SalI and NotI
restriction sites for subcloning into pVif-HA. The result-
ing construct expresses untagged Vpx protein. In all
cases, fidelity of DNA sequence and insertion of mutants
was verified by sequencing.
Immunoblotting
For immunoblot analysis of cell-associated proteins, whole
cell lysates were prepared as follows: Cells were washed
once with PBS, suspended in PBS (~200 μl/5x 106 cells)
and mixed with an equal volume of sample buffer (4%
sodium dodecyl sulfate, 125 mM Tris–HCl, pH 6.8,
10% 2-mercaptoethanol, 10% glycerol, and 0.002% bromo-
phenol blue). Proteins were solubilized by heating 10 to
15 minutes at 95°C with occasional vortexing. Cell lysates
were subjected to SDS-PAGE; proteins were transferred to
PVDF membranes and reacted with appropriate anti-
bodies as described in the text. Membranes were then
incubated with horseradish peroxidase-conjugated sec-
ondary antibodies (GE Healthcare, Piscataway NJ) and
proteins were visualized by enhanced chemiluminescence
(ECL, GE Healthcare, Piscataway NJ).
Co-immunoprecipitation analysis
HeLa cells were transfected with expression vectors for
HA-SAMHD1 and Vpx as indicated in the text. Cells
were harvested 24 h post transfection, washed with cold
PBS and lysed in lysis buffer A (50 mM Tris–HCl [pH
7.5], 150 mM NaCl, 1% [v/v] Triton X-100, 10% glycerol)
at 4°C for 20 min, then clarified by centrifugation at
10,000 x g for 10 min at 4°C. Ten to fifteen percent of
the lysate was used as an input control. The remaining
lysate was used for immunoprecipitation of HA-tagged
antigens. Cleared cell lysates were mixed with anti-HA
antibody-conjugated agarose beads (Sigma-Aldrich, Inc.,
St. Louis MO) and incubated at 4°C for 4 h. Samples
were then washed four times with lysis buffer A. Pro-
teins were eluted by boiling beads in sample buffer and
subjected to immunoblot analysis with antibodies to
SAMHD1 and Vpx.Metabolic labeling and immunoprecipitation
For pulse/chase analyses, transfected cells were har-
vested by scraping, pelleting, and suspending in 5 ml la-
beling media lacking methionine and cysteine (MP
Biomedicals, Solon OH). Cells were incubated for
15 minutes at 37°C to deplete the endogenous methio-
nine and cysteine pool. Cells were then pelleted, sus-
pended in 600 μl of labeling medium containing 350 μCi
of Expres35S35S protein labeling mix (Perkin Elmer, Shel-
ton CT) and pulse-labeled at 37°C for 15 minutes. Cells
were pelleted, suspended in complete RPMI, and equal
volumes were distributed into separate tubes (1 tube per
time point) containing 1 ml each of pre-warmed
complete RPMI. After indicated chase times, cells were
pelleted, supernatants were discarded, and cell pellets
were frozen on dry ice. Cells were lysed in 200 μl of lysis
buffer B (50 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1%
[v/v] Triton X-100) and incubated on ice for 5 minutes.
Cell lysates were pelleted at 13,000 × g for 2 minutes to
remove insoluble material. Cleared lysates were incu-
bated for 1 h at 4°C with antibody-conjugated protein
A-Sepharose. Beads were washed twice with wash buffer
(50 mM Tris pH 7.4, 300 mM NaCl, 0.1% Triton X-100).
Bound proteins were eluted by heating in sample buffer
for 10 min at 95°C, separated by SDS-PAGE, and visua-
lized by fluorography.
Immunofluorescence and confocal microscopy
HeLa cells were transfected as indicated in the text.
Transfected cells were trypsinized 3 h later and single-
cell suspensions were distributed into 12 well plates
containing 0.13 mm cover slips. Cells were grown for
overnight at 37°C in DMEM containing 10% FBS. Cells
were fixed in 10% methanol for 10 min at −20°C. Cells
were blocked with 1% BSA in PBS for 30 minutes. For
antibody staining, coverslips were incubated with appro-
priate primary antibodies in 1% BSA in PBS for
45 minutes at 37°C. Cells were washed with PBS and
incubated with appropriate secondary antibodies for
45 minutes at 37°C. Cells were then washed twice with
PBS and mounted onto microscope slides with glycerol
gelatin (Sigma-Aldrich Inc., St. Louis MO) containing
0.1 M N-propyl gallate (Sigma) to prevent photo bleach-
ing. Samples were analyzed on a Zeiss LSM410 inverted
laser scanning microscope equipped with a krypton/
argon mixed-gas laser. Images were acquired with a Plan-
Apochromat 63x/1.4 oil immersion objective (Zeiss).
Analysis of the expression of SAMHD1 splice variants
cDNA pools were generated from THP-1 cells treated
with 100 nM PMA for 24 h and used as template for a
PCR reaction using Taq polymerase (Roche) and the fol-
lowing primer sets: Δ14 primers consist of a forward pri-
mer (F14) located in exon 10 (50 GAA GTT GGA AAT
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mer (R14) spanning the junction of exons 13 and 15
(50 CTC TGG CAG AAG TTG TGA AAC ATC 30).
Δ8-9 primers consist of a forward primer (F8/9) span-
ning the junction of exons 7 and 10 (50 CTT GAA TCA
CCT GTC GAA GAT TCA TTG GAA G 30) and a re-
verse primer R8/9 in exon 15 (50 CTG CGG CTT GGT
GAA ATT TCT GTC TG 30). Plasmid controls consisted
of 1 ng of pcDNA-SAMHD1 WT, Δ14, or Δ8-9 used as
template in the PCR reaction.
dNTPase assay
HA-SAMHD1 proteins were isolated from HeLa cells
and used in a dNTPase assay using the conditions
described in Lahouassa et al. [21]. In brief, HeLa cells
transfected with HA-SAMHD1 constructs were lysed in
50 mM Tris–HCl pH 8.0, 150 mM NaCl, 1% Triton at
4°C for 20 minutes, then clarified by centrifugation at
10,000 x g for 10 minutes at 4°C. Cleared cell lysates
were mixed with anti-HA antibody-conjugated agarose
beads (Sigma-Aldrich, Inc., St. Louis MO) and incubated
at 4°C for 1.5-2 h. Samples were then washed three
times with 50 mM Tris–HCl pH 8.0, 150 mM NaCl,
0.1% Triton and once with assay buffer A (50 mM Tris–
HCl pH 8.0, 50 mM KCl, 5 mM MgCl2, 0.1% Triton).
An equal volume of assay buffer A was then added to
the bead pellet, 15% of the bead slurry reserved as an in-
put control and the rest was mixed in a 1:1 ratio with
assay buffer B (50 mM Tris–HCl pH8.0, 50 mM KCl,
5 mM MgCl2, 0.1% Triton, 400 μM dTTP, 0.5 μCi α-
[32P]-dTTP, +/− 400 μM dGTP). Reactions were incu-
bated at 37°C for 3 h with occasional mixing and
stopped by heating to 70°C for 5 minutes. A portion of
the reaction products was separated out on polyethyle-
neimine (PEI)-cellulose thin layer chromatography plates
(Sigma) using 0.8 M LiCl as the mobile phase.
Additional file
Additional file 1: Figure S1. Antiviral activity of naturally occurring
splice variants of SAMHD1. Human monocytic U937 cells were
transduced using a lentiviral vector system (pCDH; Systems Biosciences,
Mountain View CA) expressing wild-type (WT) or the indicated splicing
variants of SAMHD1. (A) Stable cell lines were selected by culturing for
4 days in the presence of 400 ng/ml of puromycin. SAMHD1 expression
was then analyzed by immunoblotting using anti-SAMHD1 antibodies.
The blot was then reprobed with antibodies to GADPH, which served as
a loading control. (B) Differentiated U937 cells expressing the indicated
protein were challenged with increasing amounts of HIV-1-GFP. Infection
was determined by measuring the percentage of GFP-positive cells using
a flow cytometer. As control, U937 cells stably transduced with the
empty vector pCDH were challenged with HIV-1-GFP. Infection
experiments were performed three times and a representative result is
shown.
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